PodcastPearls: Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Downloadable slides accompanying a podcast led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, about how they use CDK4/6 inhibitors for patients with HR-positive/HER2-negative breast cancer, including key studies on CDK4/6 inhibitors from ASCO 2021.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 643 KB
Released: August 24, 2021

Acknowledgements

Produced in collaboration with
Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding,
visit www.lillygrantoffice.com.

Related Content

Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

Exploratory analysis of EFS by residual cancer burden from KEYNOTE-522 evaluating neoadj pembrolizumab plus chemotherapy followed by adj pembrolizumab for early-stage TNBC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

PALOMA-2 study: final OS analysis with palbociclib plus letrozole in ER-positive/HER2-negative advanced breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
person default Saad A. Khan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 10, 2022 Expired: June 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings